Cargando…
HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
Diabetes is a common condition with a dismal prognosis. According to the International Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders (CVD) are the major cause of death globally. Diabetes mellitus type 2 (T2DM) increases the risk of CVD. Since 2008, the FDA...
Autores principales: | Mohanan, P.P., Jariwala, Pankaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986737/ https://www.ncbi.nlm.nih.gov/pubmed/36435205 http://dx.doi.org/10.1016/j.ihj.2022.11.010 |
Ejemplares similares
-
Bringing patient centricity to diabetes medication access in Canada
por: Glennie, Judith L, et al.
Publicado: (2016) -
GLINT: GlucoCEST in neoplastic tumors at 3 T—clinical results of GlucoCEST in gliomas
por: Bender, Benjamin, et al.
Publicado: (2021) -
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021) -
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015) -
The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM
por: Wang, Qing, et al.
Publicado: (2023)